As a prime example of cutting-edge RPTs, consider their remarkable efficacy in treating advanced prostate cancer (PCa), notably metastatic castration-resistant prostate cancer (mCRPCa) using therapies such as Lu-177-PSMA 15. Here, FOLH1 is linked to prostate cancer.